论文部分内容阅读
研究组:肾盂输尿管癌患者23例,术后2周每周行膀胱灌注吡柔比星(30mg)1次,共5次;对照组:肾盂输尿管癌患者19例,术后未行膀胱灌注。中位随访时间研究组、对照组分别为50(4~94)个月、9(3~143)个月。研究组与对照组1年非复发率分别为91.3%、73.7%,2年非复发率分别为87.0%与68.4%,组间比较,差异有统计学意义(P=0.002 5)。认为吡柔比星膀胱灌注可预防肾
Study group: Twenty-three patients with renal pelvis and ureteropelvic cancer were treated with intravesical instillation of pirarubicin (30 mg) once a week for 2 weeks after surgery. The control group was given 19 cases of ureteropelvic cancer without bladder perfusion. The median follow-up time was 50 (4 to 94) months in the study group and 9 (3 to 143) months in the control group. The one-year non-recurrence rates of the study group and the control group were 91.3% and 73.7%, respectively, and the two-year non-recurrence rates were 87.0% and 68.4% respectively. There was significant difference between the two groups (P = 0.002 5). Pirarubicin is considered to be a prophylactic treatment of bladder by intravesical instillation